SIRT1 Expression Is Associated with Good Prognosis in Colorectal Cancer
2
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Background: Silent mating type information regulation 2 homolog 1 (SIRT1), an NAD+-dependent deacetylase, might act as a tumor promoter by inhibiting p53, but may also as a tumor suppressor by inhibiting several oncogenes such as β-catenin and survivin. Deleted in breast cancer 1 (DBC1) is known as a negative regulator of SIRT1. Methods: Immunohistochemical expressions of SIRT1, DBC1, β-catenin, surviving, and p53 were evaluated using 2 mm tumor cores from 349 colorectal cancer patients for tissue microarray. Results: Overexpression of SIRT1, DBC1, survivin, and p53 was seen in 235 (67%), 183 (52%), 193 (55%), and 190 (54%) patients, respectively. Altered expression of β-catenin was identified in 246 (70%) patients. On univariate analysis, overexpression of SIRT1 (p=0.029) and altered expression of β-catenin (p=0.008) were significantly associated with longer overall survival. Expression of SIRT1 was significantly related to DBC1 (p=0.001), β-catenin (p=0.001), and survivin (p=0.002), but not with p53. On multivariate analysis, age, tumor stage, differentiation, and expression of SIRT1 were independent prognostic factors significantly associated with overall survival. Conclusions: SIRT1 overexpression is a good prognostic factor for colorectal cancer, and SIRT1 may interact with β-catenin and survivin rather than p53.
Abstract
Background: Silent mating type information regulation 2 homolog 1 (SIRT1), an NAD+-dependent deacetylase, might act as a tumor promoter by inhibiting p53, but may also as a tumor suppressor by inhibiting several oncogenes such as β-catenin and survivin. Deleted in breast cancer 1 (DBC1) is known as a negative regulator of SIRT1. Methods: Immunohistochemical expressions of SIRT1, DBC1, β-catenin, surviving, and p53 were evaluated using 2 mm tumor cores from 349 colorectal cancer patients for tissue microarray. Results: Overexpression of SIRT1, DBC1, survivin, and p53 was seen in 235 (67%), 183 (52%), 193 (55%), and 190 (54%) patients, respectively. Altered expression of β-catenin was identified in 246 (70%) patients. On univariate analysis, overexpression of SIRT1 (p=0.029) and altered expression of β-catenin (p=0.008) were significantly associated with longer overall survival. Expression of SIRT1 was significantly related to DBC1 (p=0.001), β-catenin (p=0.001), and survivin (p=0.002), but not with p53. On multivariate analysis, age, tumor stage, differentiation, and expression of SIRT1 were independent prognostic factors significantly associated with overall survival. Conclusions: SIRT1 overexpression is a good prognostic factor for colorectal cancer, and SIRT1 may interact with β-catenin and survivin rather than p53.
참고문헌 (28)
- Vaquero A, "Human SirT1 interacts with histone H1 and promotes formation of facultative heterochromatin", Mol Cell, 16, pp.93~105 (2004)
- Haigis MC, "Mammalian sirtuins: emerging roles in physiology, aging, and calorie restriction", Genes Dev, 20, pp.2913~2921 (2006)
- Stünkel W, "Function of the SIRT1 protein deacetylase in cancer", Biotechnol J, 2, pp.1360~1368 (2007)
- Kuzmichev A, "Composition and histone substrates of polycomb repressive group complexes change during cellular differentiation", Proc Natl Acad Sci U S A, 102, pp.1859~1864 (2005)
- Luo J, "Negative control of p53 by Sir2alpha promotes cell survival under stress", Cell, 107, pp.137~148 (2001)
- Firestein R, "The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth", PLoS One, 3, pp.e2020~ (2008)
- Wang RH, "Interplay among BRCA1, SIRT1, and survivin during BRCA1-associated tumorigenesis", Mol Cell, 32, pp.11~20 (2008)
- Jang SH, "Loss of SIRT1 histone deacetylase expression associates with tumour progression in colorectal adenocarcinoma", J Clin Pathol, 65, pp.735~739 (2012)
- Nosho K, "SIRT1 histone deacetylase expression is associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer", Mod Pathol, 22, pp.922~932 (2009)
- Kabra N, "SirT1 is an inhibitor of proliferation and tumor formation in colon cancer", J Biol Chem, 284, pp.18210~18217 (2009)
- 강영란, "Expression of SIRT1 and DBC1 in Gastric Adenocarcinoma", Journal of Pathology and Translational Medicine, 46(6), pp.523~531 (2012), 대한병리학회
- Cha EJ, "Expression of DBC1 and SIRT1 is associated with poor prognosis of gastric carcinoma", Clin Cancer Res, 15, pp.4453~4459 (2009)
- Hamaguchi M, "DBC2, a candidate for a tumor suppressor gene involved in breast cancer", Proc Natl Acad Sci U S A, 99, pp.13647~13652 (2002)
- Kim JE, "DBC1 is a negative regulator of SIRT1", Nature, 451, pp.583~586 (2008)
- Lee H, "Expression of DBC1 and SIRT1 is associated with poor prognosis for breast carcinoma", Hum Pathol, 42, pp.204~213 (2011)
- Zhang Y, "DBC1 is over-expressed and associated with poor prognosis in colorectal cancer", Int J Clin Oncol (2013)
- Czyzewska J, "The expression of E-cadherin-catenin complex in patients with advanced gastric cancer: role in formation of metastasis", Folia Histochem Cytobiol, 48, pp.37~45 (2010)
- Salim T, "Nuclear expression of glycogen synthase kinase-3beta and lack of membranous beta-catenin is correlated with poor survival in colon cancer", Int J Cancer, 133, pp.807~815 (2013)
- Ruchaud S, "Chromosomal passengers : conducting cell division", Nat Rev Mol Cell Biol, 8, pp.798~812 (2007)
- Mirza A, "Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway", Oncogene, 21, pp.2613~2622 (2002)
- Bosman FT, "WHO classification of tumours of the digestive system" (2010), IARC Press
- Edge SB, "AJCC cancer staging manual" (2010), Springer
- Allegra CJ, "Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes’ B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study", J Clin Oncol, 21, pp.241~250 (2003)
- Tetsu O, "Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells", Nature, 398, pp.422~426 (1999)
- Ikeda S, "Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3beta and beta-catenin and promotes GSK-3beta-dependent phosphorylation of beta-catenin", EMBO J, 17, pp.1371~1384 (1998)
- Chen L, "Survivin status affects prognosis and chemosensitivity in epithelial ovarian cancer", Int J Gynecol Cancer, 23, pp.256~263 (2013)
- Meng JR, "TFF3 and survivin expressions associate with a lower survival rate in gastric cancer", Clin Exp Med (2012)
- Qi G, "Intracellular localization of survivin determines biological behavior in colorectal cancer", Oncol Rep, 22, pp.557~562 (2009)